glaxosmithkline

M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE...

While the fate of the 2010 health care reform law may rest in the hands of the Supreme Court, the nation's focus on health care has returned for the moment. For investors, the following health care picks all pay a dividend and have seen double-digit percentage growth in their share price since the...

First Trust Consumer Staples AlphaDEX (NYSE: FXG) is up more than 20% year to date. The investment seeks results that correspond generally to the price and yield of an equity index called the StrataQuant Consumer Staples Index. Top holdings include Green Mountain Coffee Roasters (NASDAQ: GMCR),...

Forest Laboratories (NYSE: FRX) and Watson Pharmaceuticals (NYSE: WPI) reached new 52-week highs of $40.52 and $66.00 per share, respectively, in Wednesday's trading session. Forest Labs saw an upgrade from Argus and Duncan-Williams upgraded its price target on the stock to $45 in the wake of...

Colgate-Palmolive (NYSE: CL) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $89.28 and $39.56 per share, respectively, late in Monday's trading session. Colgate just announced the completion of its purchase of the Sanex personal care brand from Unilever (NYSE: UL). Colgate has a...

CIGNA (NYSE: CI) and Forest Laboratories (NYSE: FRX) reached new 52-week highs of $50.70 and $37.87 per share, respectively, on Thursday but were lower in premarket trading Friday. CIGNA was raised to Outperform as yesterday's Bull of the Day at Zacks. The company has a market cap of $13.6...

Piper Jaffray is defending Theravance, Inc. (NASDAQ: THRX) following a delayed sell-off on Friday prompted by Novartis' (NYSE: NVS) decision to not pursue US development of a competing once daily long acting beta agonist (LABA) and inhaled corticosteroid (ICS) combination drug for COPD/Asthma. “...

Jefferies is upgrading GlaxoSmithKline (NYSE: GSK) to Buy from Hold. “After underperforming the UK market by 11% since we moved our rating to hold from Buy on 15 September 2010, we have upgraded the shares to Buy,” Jefferies writes. “We expect that the re-introduction of the share repurchase...

The holiday season is here and, it brings a vast array of delicious products with it. From big dinners, to desserts galore, the holidays are typically a chance to attack the buffet at full-force. Odds are Santa won't be the only one packing on a few pounds after overdosing on milk and cookies. A...

Yesterday evening, Valeant Pharmaceuticals International (NYSE: VRX) and GlaxoSmithKline PLC (NYSE: GSK) jointly announced receipt of a Complete Response FDA letter for Potiga (ezogabine/retigabine), an investigational anti-epileptic drug for the adjunctive treatment of partialonset seizure in...

Goldman Sachs has adopted a more guarded stance for Colgate-Palmolive (NYSE: CL) due to challenges from Procter & Gamble (NYSE: PG) and GlaxoSmithKline (NYSE: GSK). In the research note, Goldman writes "P&G's push into several large oral care markets has gotten the bulk of investor...

Goldman Sachs reports on Parexel International Corporation (NASDAQ: PXRL) and Pharmaceutical Product Development, Inc. (NASDAQ: PPDI), stating that GlaxoSmithKline (NYSE: GSK) is negotiating contracts to enter into strategic relationships with these late-stage CROs: For Parexel, Goldman states: "We...